$RVNC News
Last published 1y ago
- 1y agoRVNCRevance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNCGlobeNewswireNEW YORK, March 03, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ:RVNC). Shareholders who purchased shares of RVNC during the class
- 1y agoRVNCRevance Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - RVNCPR NewswireThe Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of...
- 1y agoRVNCInvestors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCPR NewswireThe Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of...
- 1y agoRVNCInvestors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights – RVNCGlobeNewswireNEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ:RVNC). Shareholders who purchased shares of RVNC during the class period
- 1y agoRVNCCrown Laboratories Completes Acquisition of Revance TherapeuticsBusiness WireYesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition of Revance
- 1y agoRVNCCrown Laboratories and Revance Therapeutics Announce Expiration of Tender OfferPR NewswireCrown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today announced that the tender offer to purchase all...
- 1y agoRVNCRevance Stockholders Urged to Tender Their Shares in Support of Crown Transaction by the February 4th DeadlinePR NewswireCrown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today reminded Revance stockholders of the...
- 1y agoRVNCShareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCPR NewswireThe Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of...
- 1y agoDRMARVNCDermata and Revance Enter Clinical Trial Collaboration Agreement for the Topical Application of Xyngari(TM) with Daxxify(R)ACCESS NewswireThe Companies intend to first initiate a Phase 2a clinical trial evaluating Xyngari™ with Daxxify® to treat primary axillary hyperhidrosis -If successful, the Companies may explore clinical development in
- 1y agoRVNCCrown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender OfferPR NewswireCrown Laboratories, Inc. ("Crown") and Revance Therapeutics, Inc. (NASDAQ: RVNC) ("Revance"), today announced that, on January 17, 2025, they amended ...
- 1y agoRVNCCrown Laboratories and Revance Amend the A&R Merger Agreement to Increase Offer Price to $3.65 per Share and Extend Existing Tender OfferBusiness WireIncreased offer price to $3.65 per share, a $0.55 per share increase Improved offer unanimously approved by Revance Board of Directors Crown to extend tender offer until 11:59 p.m., Eastern Time, on February 4,
- 1y agoRVNCInvestors in Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCPR NewswireThe Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of...
- 1y agoRVNCRevance Therapeutics, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCPR NewswireThe Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of...
- 1y agoRVNCShareholders of Revance Therapeutics, Inc. Should Contact The Gross Law Firm Before March 4, 2025 to Discuss Your Rights - RVNCGlobeNewswireNEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ:RVNC). Shareholders who purchased shares of RVNC during the class period
- 1y agoRVNCCrown Laboratories Extension of Tender Offer to Acquire Revance Therapeutics, Inc.PR NewswireCrown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that, at the request of...
- 1y agoRVNCThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of March 4, 2025 in Revance Lawsuit - RVNCPR NewswireThe Gross Law Firm issues the following notice to shareholders of Revance Therapeutics, Inc. (NASDAQ: RVNC). Shareholders who purchased shares of...
- 1y agoRVNCTeoxane SA Announces Superior Proposal to Acquire Revance Therapeutics for $3.60 per Share in CashPR NewswireTeoxane SA today announced that on January 6, 2025, it submitted a proposal to the Board of Directors of Revance Therapeutics, Inc. (Nasdaq: RVNC) to ...
- 1y agoRVNCCrown Laboratories Commences Friendly Tender Offer for All Outstanding Common Shares of Revance Therapeutics at $3.10 per sharePR NewswireCrown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, today announced that it has commenced a cash ...
- 1y agoRVNCCrown Laboratories and Revance Enter into Amended and Restated Merger AgreementPR NewswireCrown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. ("Revance")...
- 1y agoRVNCCrown Laboratories and Revance Enter into Amended and Restated Merger AgreementBusiness WireCrown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. ("Revance") (NASDAQ:RVNC), a biotechnology company aimed at setting the new
- 2y agoGLYCPFIERCMRVNCKuehn Law Encourages PFIE, GLYC, RVNC, and RCM Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoARCKRVNCZUOKuehn Law Encourages ZUO, ARC, K, and RVNC Investors to Contact Law FirmGlobeNewswireNEW YORK, Oct. 18, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures
- 2y agoRVNCRVNC Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Revance Therapeutics to Crown LaboratoriesGlobeNewswireMONSEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Revance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance") to Crown Laboratories,
- 2y agoRVNCCrown Laboratories and Revance Announce Entry Into Merger AgreementPR NewswireCrown Laboratories, Inc. ("Crown"), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. ("Revance")...
- 2y agoRVNCRevance Therapeutics, Inc. (RVNC) Q2 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRVNCRevance Reports Second Quarter 2024 Financial Results, Provides Corporate UpdateBusiness Wire- Q2 total DAXXIFY® and RHA® (by Teoxane SA) product revenue of $65.3 million, a YoY increase of 20%. - Q2 DAXXIFY net revenue of $28.7 million, a YoY increase of 27%. - Q2 DAXXIFY aesthetic units sold
- 2y agoRVNCRevance to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024Business WireConference Call Scheduled for Thursday, August 8, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will release second quarter 2024 financial results on Thursday, August
- 2y agoRVNCRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireRevance Therapeutics, Inc. (NASDAQ:RVNC) today announced new hire grants totaling an aggregate of 104,800 inducement restricted stock units ("RSUs") to 31 employees. The RSUs vest over four years, with 25% of the
- 2y agoRVNCRevance to Participate in Upcoming Investor ConferencesBusiness WireRevance Therapeutics, Inc. (NASDAQ:RVNC) today announced that the company will be participating in the following investor conferences. William Blair 44th Annual Growth Stock Conference Chief Financial Officer Tobin
- 2y agoRVNCRevance Therapeutics Inc. (RVNC) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRVNCRevance Reports First Quarter 2024 Financial Results, Provides Corporate UpdateBusiness Wire- Total net product revenue (DAXXIFY® and RHA® Collection) of $51.7 million, a YoY increase of 13%. - DAXXIFY® net revenue of $22.1 million, after a reduction of $2.0 million related to a consumer
- 2y agoRVNCRevance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical DystoniaBusiness WireDAXXIFY® for the treatment of cervical dystonia is the first and only peptide-formulated, long-lasting neurotoxin that offers the potential to improve duration of symptom control1 Revance has received a
- 2y agoRVNCRevance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024Business WireConference Call Scheduled for Thursday, May 9, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (NASDAQ:RVNC), today announced that the company will release first quarter 2024 financial results on Thursday, May 9,
- 2y agoRVNCRevance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual MeetingBusiness Wire– Two presentations highlighting data on DAXXIFY® for the treatment of cervical dystonia, including a new analysis from ASPEN trials assessing patient-desired retreatment intervals and one abstract examining the
- 2y agoRVNCRevance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireRevance Therapeutics, Inc. (NASDAQ:RVNC) today announced new hire grants totaling an aggregate of 222,452 inducement restricted stock units ("RSUs") to 29 employees. The RSUs vest over four years, with 25% of the
- 2y agoRVNCRevance Announces Pricing of $100.0 Million Public Offering of Common StockBusiness WireRevance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance" or the "Company") today announced the pricing of an underwritten public offering of 16,000,000 shares of its common stock. The shares of common stock are being offered
- 2y agoRVNCRevance Announces Proposed Public Offering of Common StockBusiness WireRevance Therapeutics, Inc. (NASDAQ:RVNC) ("Revance" or the "Company") today announced a proposed underwritten public offering of $100 million of its common stock. In addition, the Company expects to grant the
- 2y agoRVNCRevance Therapeutics Inc. (RVNC) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRVNCRevance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate UpdateBusiness Wire– Q4 and full year 2023 product revenue (DAXXIFY® and RHA® Collection) of $58.5 million and $212.7 million, representing approximately 28% and 80% YoY growth, respectively. – Q4 DAXXIFY volume up 22% over Q3
- 2y agoRVNCRevance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024Business WireConference Call Scheduled for Wednesday, February 28, 2024 at 4:30 p.m. ET. Revance Therapeutics, Inc. (RVNC), today announced that the company will release fourth quarter and full year 2023 financial results on
- 2y agoRVNCRevance to Participate in Upcoming Investor ConferencesBusiness WireRevance Therapeutics, Inc. (RVNC) today announced that the company will be participating in the following investor conferences. Cowen 44th Annual Healthcare Conference Chief Executive Officer, Mark Foley and Chief
- 2y agoRVNCRevance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®Business Wire- CMS streamlines reimbursement for DAXXIFY with assignment of permanent J-code - - Peer-reviewed publication of DAXXIFY pivotal data in therapeutics reinforces the products long duration of effect and favorable
- 2y agoRVNCRevance to Participate in the Guggenheim 6th Annual Biotechnology ConferenceBusiness WireRevance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the Guggenheim Healthcare Talks, 6th Annual Biotechnology Conference, taking place February 7-8, 2024, in New York, New York.
- 2y agoRVNCRevance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial OutlookBusiness Wire– Q4 DAXXIFY® volume sold up 22% over Q3, reflecting positive feedback on the product's performance profile and the new pricing strategy. – Preliminary unaudited Q4 and full year 2023 product revenue (DAXXIFY and
- 3y agoRVNCRevance Reports Third Quarter 2023 Financial Results, Provides Corporate UpdateBusiness Wire– Q3 total product revenue of $54.1 million, a YoY increase of 107.5%. – Q3 DAXXIFY® revenue of $22.0 million, and first full year revenue post approval of $71.0 million. – Q3 RHA® Collection revenue of $32.1
- 3y agoRVNCRevance Appoints Erica Jordan as Chief Commercial Officer, AestheticsBusiness WireRevance Therapeutics, Inc. (NASDAQ:RVNC) today announced the appointment of Erica Jordan, Senior Vice President of Commercial to Chief Commercial Officer (CCO), Aesthetics. As CCO, Erica will have global responsibility
- 3y agoRVNCRevance to Participate in Upcoming Investor ConferencesBusiness WireRevance Therapeutics, Inc. (RVNC), today announced that the company will be participating in the following investor conferences. Stifel 2023 Healthcare Conference Chief Financial Officer, Tobin Schilke, is scheduled
- 3y agoRVNCRevance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023Business WireConference Call Scheduled for Wednesday, November 8, 2023 at 4:30 p.m. ET Revance Therapeutics, Inc. (RVNC) today announced that the company will release third quarter 2023 financial results on Wednesday, November 8,
- 3y agoRVNCDAXXIFY® Becomes First Facial Injectable to be Named to TIME's Best InventionsBusiness Wire- DAXXIFY® (daxibotulinumtoxinA-lanm) for Injection named to TIME's list of the best inventions of 2023. - DAXXIFY® is a long-lasting peptide enhanced neuromodulator that delivers the first true innovation
- 3y agoRVNCRevance Provides Corporate Update at Investor DayBusiness WireRevance Therapeutics, Inc. (RVNC) announced that the company is hosting its Investor Day today, September 19, 2023, from 9:30 am ET to 12:00 pm ET. The Investor Day will include management presentations on Revance's